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Abstract
Background: Dopamine-activated signaling regulates locomotor and emotional responses and
alterations in dopamine-signaling are responsible of several psychomotor disorders. In order to
identify specific functions of these pathways, the Cre/loxP system has been used. Here, we describe
the generation and the characterization of a transgenic mouse line expressing the Cre recombinase
in dopaminoceptive neurons. To this purpose, we used as expression vector a 140 kb yeast artificial
chromosome (YAC) containing the dopamine D1 receptor gene (Drd1a).
Results:  In the chosen line, D1Cre, the spatio-temporal pattern of Cre expression closely
recapitulated that of the endogenous Drd1a gene, as assessed by immunohistological approaches in
embryonic and adult stages. Efficiency of recombination was confirmed by crossing D1Cre with
three different loxP lines (Creb1loxP, CaMKIVloxP and GRloxP) and with the R26R reporter. In the three
loxP lines studied, recombination was restricted to the area of Cre expression.
Conclusion: In view of the patterns of recombination restricted to the major dopaminoceptive
regions as seen in the context of the CREB, CaMKIV and GR mutations, the D1Cre line will be a
useful tool to dissect the contributions of specific genes to biological processes involving dopamine
signaling.
Background
Although dopaminergic neurons are few (e.g. 10–20,000
in the rat brain), they regulate a number of physiological,
behavioral and cognitive functions, including regulation
of locomotor activity, incentive behaviors, short-term and
stimulus-dependent memory systems [1-3]. Dysfunction
of the dopaminergic system and its targets underlie major
human disorders such as Parkinson's disease, Hunting-
ton's disease, schizophrenia and addiction to drugs of
abuse [4-6]. Five dopamine receptors, termed D1, D2,D3,
D4 and D5, encoded by five different genes (Drd1a, Drd2,
Drd3, Drd4 and Drd5 respectively) have been identified
[7,8]. The elucidation of the signaling properties of
dopaminoceptive neurons is of central importance for the
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development of therapeutic strategies to treat dysfunc-
tions of the dopaminergic system.
In the past years, use of the Cre/loxP system has enabled
generation of cell-specific mutations In the central nerv-
ous system, efforts have generally been devoted to the
generation of region-specific mutations using promoters
to drive the expression of Cre recombinase in specific
brain areas [9-11]. In order to target the dopaminoceptive
neurons, we have generated a transgenic line that
expresses Cre recombinase in dopaminoceptive neurons
under the control of the dopamine D1 receptor gene
(D1Cre), by using the genomic locus of a dopamine D1
receptor gene cloned in a YAC vector.
Here we examine the cellular expression of Cre recombi-
nase in D1Cre transgenic mice by immunohistochemistry
in combination with in situ hybridization, to compare it
with the expression of D1 receptor mRNA and other
dopaminoceptive molecular markers. The activity of the
Cre was confirmed by loss of CREB, CaMKIV and GR pro-
teins in the respective conditional mutants and by induc-
tion of beta-galactosidase activity in the R26RD1Cre
reporter mice.
Results
A 140 kb yeast artificial chromosome (YAC) containing
the entire dopamine D1 receptor gene (Drd1a) was iso-
lated by screening a mouse genomic YAC library [12]. The
YAC encompasses the entire Drd1a gene including 40 kb
of upstream and 100 kb of downstream sequences. The
coding sequence for the nuclear localized nlsCre [13] was
introduced into the Drd1a gene by homologous recombi-
nation in yeast. To minimize the chances of altering pos-
sible regulatory elements, we avoided the use of a
heterologous polyadenylation sequence and minimized
the deletion of the Drd1a coding sequence. Specifically,
the homology regions were chosen so that the ATG of the
nlsCre would replace the ATG of the Drd1a gene and the
STOP codon of the nlsCre would interrupt the Drd1a
open reading frame after its last possible internal ATG.
The modified YAC was used to generate 5 independent
transgenic lines (D1Cre lines A, R, S, T and U). Two lines
(T and U) carried incomplete copies of the transgene as
assessed by screening for the presence of the extremities of
the YAC arms (data not shown). Examination of Cre
expression by immunohistochemistry in the three
remaining lines (A, R and S) revealed a virtually identical
pattern of expression (Fig. 1). Moreover, the level of
expression was in direct correlation with the copy number
of the transgene (Fig. 1). Detailed analysis of the Cre
expression pattern was conducted with line A which car-
ries three copies of the YAC transgene. Expression was
prominent in the major projections areas of the dopamin-
ergic system, including striatum, nucleus accumbens,
olfactory tubercles and prefrontal cortex (Fig. 2). Clear but
lower expression was seen in layer VI of the cortex. In hip-
pocampus, CA2 and scattered cells in the dentate gyrus
expressed Cre (Fig. 2). Several thalamic nuclei and the
ventromedian hypothalamic nucleus also expressed Cre
(Fig. 2). In retina, robust staining was observed in the
inner nuclear layer (Fig. 2). In order to verify that Cre is
expressed in neurons expressing the D1R mRNA, we have
performed in situ hybridization with a specific D1R ribo-
probe in combination with immunohistochemical detec-
tion of Cre expression in striatum and cortex (Fig. 3a, b).
The dynamics of Cre expression was examined during
embryonic development and the postnatal period. D1R
mRNA expression in the striatum has been reported at
E13 in mice [14], therefore we have analyzed Cre protein
at E14.5. At E14.5, Cre could not be detected in striatal
anlage nor in any brain region (Fig. 4a–c and data not
shown). Cre expressing cells appeared in striatal patches,
the so-called striosomes at E16.5 and a only very few
weakly expressing cells could be detected in the develop-
ing cortex (Fig. 4d–f). At E18.5 the number of Cre express-
ing cells increased in the striatum as well as in the
presumptive layer VI of the cortex (Fig. 4g–i). At postnatal
days 0 and 3 (P0 and P3), Cre recombinase was still pre-
dominant in the striosomal neurons and layer VI of the
cortex (Fig. 5). At P6, Cre expression started to be seen
between the patches. Cre expression expanded progres-
sively until the adult stage. Transient and very weak
expression was observed in the CA1 region of the hippoc-
ampus and in layer IV of the cortex (Fig. 5). These results
indicate that Cre starts to be expressed, albeit at low levels,
at E16 in the striosomal neurons of the striatum. At the
end of the first week after birth, Cre expression is seen also
in cell bodies of the matrix, recapitulating the pattern of
expression described for D1R mRNA [15-17].
In order to assess the specificity and the onset of Cre activ-
ity we have crossed D1Cre transgenic mice with the R26R
reporter line [18] (Figure 6). We rule out the possibility of
recombination in regions outside the CNS as shown at
E11 by beta-galactosidase assay in the R26RD1Cre reporter
mice (Fig. 6a). Interestingly, we were able to detect Cre
activity in the tectum above the mesencephalic region
(Fig. 6d). The pattern of recombination induced by Cre
recombinase was also analyzed in the adult brains (Fig.
6b, c, e, f). Beta-galactosidase activity in R26RD1Cre was
induced not only in the major areas of Cre expression
shown in Figure 2, but also layers in IV to VI in the cortex
(Fig. 6b, f) and in the CA1 region (Fig. 6c), expressing the
Cre recombinase in early postnatal development (Figure
5).BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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We next examined whether Cre expression was confined
to a specific subpopulation of striatal neurons. In the stria-
tum, two subtypes of spiny neurons are involved in the so
called "direct-" and "indirect-pathway". The direct path-
way originates from striatal neurons projecting directly to
the medial globus pallidus (GPm) and the substantia
nigra pars reticulata (SNr). The neurons contributing to
the indirect pathway are instead connected to these areas
via the basal ganglia. Although it is still a matter of debate,
it has been classically thought that the direct pathway neu-
rons express the D1 dopamine receptor and the indirect-
pathway neurons express the D2 receptor (D2R) [19,20].
In order to establish whether Cre expression is confined to
a specific subpopulation, we retrogradely labeled neurons
from the striatonigral pathway by stereotaxic injection of
red fluorescent latex spheres into the substantia nigra pars
reticulata and localized Cre within the striatum by
immunofluorescence (Fig. 7a). Double labeling of neu-
ron-specific class III beta-tubulin and Cre recombinase
showed that the majority of striatal neurons express the
Cre recombinase driven by the Drd1a gene (Fig. 7b). This
experiment showed that Cre expression was not restricted
Position-independent and copy-number dependent expression of the D1Cre YAC transgene Figure 1
Position-independent and copy-number dependent expression of the D1Cre YAC transgene. (a) Schematic rep-
resentation of the modified D1Cre YAC. (b) Schematic view of the known distribution of Drd1a mRNA [29, 38].(c-e) Expres-
sion pattern of Cre as revealed by immunohistochemistry in D1Cre transgenic lines. (c) Line R, (d) line A and (e) line S. The 
accompanying Southern blots show the copy number dependent expression of Cre. The upper band is the endogenous Drd1a 
gene and the lower band is the D1Cre YAC transgene. Abbreviations: CL: centrolateral thalamic nucleus; CM: central medial 
thalamic nucleus; CPu: caudate putamen; DG: dentate gyrus; LD: laterodorsal thalamic nucleus; VL: ventrolateral thalamic 
nucleus;VM: ventromedial thalamic nucleus; VMH: ventromedial hypothalamic nucleus. Magnification: (b-e) 5×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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to the retrogradely labeled neurons which correspond to
neurons of the direct pathway that project directly to the
substantia nigra.
To further assess the subpopulation specificity of the
D1Cre transgene, we checked whether also D2R-positive
cells express Cre protein in the striatum. Therefore, we
performed in situ hybridization by using a D2R-specific
riboprobe followed by immunohistochemistry with Cre-
specific antibody (Fig. 7c). This experiment shows that
D1Cre is expressed also in about 40% of D2R-expressing
cells, and that only about 20% of D2R positive cells do
not express Cre at detectable levels (Fig. 7d) while about
40% of the neurons express D1Cre but not D2R mRNA.
Therefore, we conclude that at least 80% of the striatal
neurons express D1Cre. It has to be mentioned that some
studies indicate that there is only very little overlap in the
number of neurons expressing both receptors [19,21].
Detailed pattern of Cre expression Figure 2
Detailed pattern of Cre expression. (a-i) Immunohistochemical localization of Cre expression. (a) Basal ganglia, (b) pre-
frontal cortex, (c) cortex, (d) olfactory nucleus, (e) hippocampus, (f) septum, (g) thalamus, (h) hypothalamus and (i) retina. 
Abbreviations: Acb: nucleus accumbens; CA2: hippocampus CA2 field; CL: centrolateral thalamic nucleus; CM: central medial 
thalamic nucleus; CPu: caudate putamen; DG: dentate gyrus; GCL: ganglion cell layer; INL: inner nuclear layer; ipl: inner plexi-
form layer; LD: laterodorsal thalamic nucleus; ONL: outer nuclear layer; opl: outer plexiform layer. Tu: olfactory tubercle; VI: 
layer VI of the cortex; VMH: ventromedial hypothalamic nucleus; a-b, c-h are coronal sections; c is a sagittal section. Magnifi-
cation: (a-b) 25×; (c) 5×; (d-h) 50×; (i) 100×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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According to these studies we were not expecting expres-
sion of D1Cre in D2R positive cells to such an extent.
However, depending on the sensitivity and resolution of
the adopted technical approach, others studies reveal that
there is a higher degree of overlap [22] and that possibly
all dopamine receptor-containing neurons, in the stria-
tum, express both receptor types [23,24]. Our study does
not solve this debate about the degree of overlap between
D1R and D2R, however, the finding that Cre expression is
detectable in both neuronal subpopulations, D1R- and/or
D2R-expressing neurons, suggests that these receptors are
at least partially coexpressed in a certain proportion of
striatal neurons (about 40%).
The expression of D1Cre not only in D1R positive neu-
rons (Fig. 3a), but also in D2R positive cells (Fig. 7d),
makes the D1Cre line suitable for gene inactivation in vir-
tually all dopaminoceptive neurons of the striatum. The
pattern of recombination induced by Cre recombinase
was verified by crossing D1Cre transgenic animals to 3
loxP lines, Creb1loxP [25], CaMKIVloxP [26], GRloxP [18,27].
Recombination was visualized by loss of CREB, CaMKIV
and GR proteins in the respective mutants. Loss of CREB,
CaMKIV and GR proteins was extensive (at least 90%) in
the main regions of Cre expression, striatum, nucleus
accumbens, olfactory tubercles, and layer VI of the cortex
(Figure 8). In the hippocampus, expression of Cre in the
CA2 subfield results in loss of CREB, and CaMKIV in the
corresponding cells. No or very marginal loss of CREB,
CaMKIV and GR was observed in CA1 and layer IV of the
cortex, in spite of the transient expression of Cre during
the early postnatal period. These results underscore the
importance of verifying recombination in the context of
the loxP modified allele of interest.
Discussion
The pattern of expression obtained with the D1Cre YAC
transgene was very reproducible between transgenic lines.
The expression level was essentially only dependent on
the copy number of the transgene. These observations
illustrate well the properties of transgenes based on large
DNA segments: position-independent and copy-number
dependent expression of the transgene. This correlation
between expression pattern and copy number usually
does not apply to plasmid-based constructs [28]. The pat-
tern of Cre expression as seen in the D1Cre transgenic ani-
mals is very close to the pattern of expression of the
endogenous  Drd1a  gene reported in previous in situ
hybridization studies [29]. Moreover, the developmental
and postnatal patterns of expression match the patterns
described for the endogenous Drd1a  gene [15-17]. We
have also performed in situ hybridization with D1R ribo-
probe in combination with Cre immunohistochemistry in
adult cortex and striatum and found high levels of overlap
(Fig. 3a, b).
Several publications have suggested that D1 and D2 recep-
tors are segregated specifically on distinct neuronal popu-
lations of the rat striatum that projects directly to
substantia nigra pars reticulata and to globus pallidus
respectively [20,30]. Some other publications have how-
ever demonstrated that D1 and D2 might actually be coex-
pressed [22-24]. These discordant studies clearly indicate
that a fine modulation of expression levels of D1R and
D2R takes place in the dopaminoceptive neurons. In our
transgenic line, we observe that Cre is expressed in a
majority of striatal neurons, but it remains open whether
our vector, even though it contains large segments of 5'-
and 3'- flanking sequences, carries all necessary elements
required to achieve this fine modulation of expression lev-
els within striatum.
A potential application of D1Cre transgene for isolation
of mutated dopaminoceptive cells is represented by the
generation of double transgenic mice with BAC-D1GFP
and BAC-D2GFP obtained by the GENSAT BAC Trans-
genic project [31]. The D1Cre expression pattern matches
quite closely the BAC-D1GFP pattern in the medium
spiny neurons of the striatum, therefore one would expect
to isolate recombined GFP positive cells. However deeper
analysis by costaining is required to compare the two
transgenic lines.
Expression of D1Cre in neurons expressing D1R mRNA Figure 3
Expression of D1Cre in neurons expressing D1R 
mRNA. In situ hybridization with a riboprobe specific for 
D1R mRNA (blue) followed by immunohistochemistry with 
Cre specific antibody (brown) showing D1Cre and D1R 
mRNA coexpression in striatal neurons (a) and in the cortex 
(b). (a,b) 1000×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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When recombination was verified in the context of three
loxP-modified alleles, loss of the respective proteins were
largely confined to the main areas of Cre expression. Thus
loss of CREB, CaMKIV and GR were extensive in striatum,
layer VI of the cortex and CA2 of the hippocampus (Figure
8). However, induction of beta-galactosidase activity in
R26RD1Cre reporter mice showed a more widespread pat-
tern of recombination in layer IV of the cortex and in the
CA1 of the hippocampus (Figure 6). One possible expla-
nation for this could be that scattered recombination, as
caused by weak and transient Cre expression occurring at
early postnatal stages (Figure 5), is easily underestimated
when followed by loss of the respective protein but very
visible when revealed by beta-galactosidase staining. This
may be also related to a tissue-specific difference in the
stability of CREB, CaMKIV and GR proteins in CA1 and
layer IV.
In view of the patterns of recombination restricted to the
major dopaminoceptive regions as seen in the context of
the CREB, CaMKIV and GR mutations, the D1Cre line
should be useful to evaluate the contribution of these, and
others, signaling molecules to the dopaminergic system.
The D1Cre line, combined with specific pharmacological
Cre expression during embryonic development Figure 4
Cre expression during embryonic development. DAPI staining on coronal sections of embryos at E14.5, E16.5 and E18.5 
(a,d,g). The regions analyzed in striatum and cortex by immunohistochemistry with Cre antibody are boxed. No Cre positive 
cells at E14.5 are visible (b-c). At E16.5 Cre expressing cells are detected in the striatum (str) and a few scattered weakly 
expressing cells are observed in the cortex (cx) (e-f). At E18.5, more Cre positive cells are found in the striatum. Cre expres-
sion appeared in the cortical plate, in the presumptive layer VI (h-i). Magnification: (a,d,g) 100× (b,c,e,f,h,i) 200×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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treatment may provide a powerful tool do genetically dis-
sect signalling pathways underlying dopaminergic neuro-
transmission.
Conclusion
We present the generation and characterization of a trans-
genic mouse line expressing the Cre recombinase under
the control of the D1R regulatory elements. We show that
this transgenic line can be used successfully for the condi-
tional ablation of specific genes important for biological
processes involving dopamine signaling.
Methods
D1Cre YAC construction
The small insert Princeton mouse YAC library [12] was
screened by PCR (primers: 5'-TTT CAT CCT CCC TCA TAA
GC-3' and 5'-TTCGACAGGGTTTCCATTAC-3'). To allow
for subsequent modification, the YAC was transferred into
the yeast strain YPH925 [33]. To insert the Cre recombi-
nase into the Drd1a  gene, a targeting vector was con-
structed by cloning a 800 bp 5' homology region
(primers:5'-GGG GCG GCC GCG GTC CTG CCC TAA
GAA CGA G-3'and 5'-ACC AAG CTT AGC CAG ACT TCC
Cre expression during postnatal development Figure 5
Cre expression during postnatal development. Immunohistochemical localization of Cre. At P0 (a-c) and P3 (d-f), stri-
atal Cre is restricted to the patch compartment (arrowheads). Expression in layer VI of the cortex is present already at birth. 
Transient and very weak expression is visible in the CA1 hippocampal region (a,d,g) and in layer IV of the cortex (c,f,i). At P6 
(g-i), striatal Cre expression starts in the matrix compartment (asterisk), between the patches (arrowheads). Expression in 
CA1 and cortex layer IV disappears progressively. Magnification: (a,b,d,e,g,h) 50×; (c,f,i) 100×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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Cre activity in embryonic and adult brain in R26RD1Cre mice Figure 6
Cre activity in embryonic and adult brain in R26RD1Cre mice. (a) Cre activity is analyzed by expression of beta-galactos-
idase activity (blue staining) at E10.5. The reporter mice are heterozygous for the R26R allele. Positive signal is present in the 
developing brain at this stage in the tectum above the mesencephalic fold (boxed area), as shown also in (d, arrowhead). In the 
adult brain, beta-galactosidase activity analyzed in coronal vibratome sections is present in striatum (b,e), cortex (b,f) and hip-
pocampus (c). CA2: hippocampus CA2 field; DG: dentate gyrus; VI: layer VI of the cortex. Magnification: (a) 20×, (d) 40×, (b,c) 
50×, (e,f) 100×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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CCC-3'), the nlsCre open reading frame (HindIII-EcoRI
fragment from pHD2 nlsCre, [13]) and a 500 bp 3' hom-
ology region (primers: 5'-TTT GGG TGG GCG AAT TCT
TCC CTG AAC CCC ATT ATT TAT-3' and 5'-GAT AAT ACT
CCC AAA CTG GAT TTC AGA GCC GAA GTC ATT T-3')
bearing a unique XbaI restirction site into the NotI and
BamHI sites of the pRS306 vector [34]. The XbaI linearized
targeting vector was then used to modify the Drd1a con-
taining YAC by classical "pop-in pop-out" modification
[35].
Generation of transgenic animals
The YAC DNA from one of the positive colonies was puri-
fied as described [36] and microinjected into the pronu-
cleus of FVB/N oocytes. Founders were identified by
Southern blot analysis of BamHI digested genomic DNA
using the 5' homology region as a probe. Since this probe
hybridizes identically to the endogenous Drd1a gene and
to the modified YAC, it was used to determine the copy
number of the transgene in the various founders. For sub-
sequent routine genotyping, dot blot analysis was per-
Cre expression in striatal neurons Figure 7
Cre expression in striatal neurons. (a) Retrograde labeling of striatonigral neurons within the striatum (red fluorescence). 
Cre was labeled by immunofluorescence (green fluorescence). (b) Double immunofluorescence against Cre (green fluores-
cence) and neuron-specific class III tubulin (TujI monoclonal antibody, red fluorescence). (c) Expression of Cre protein in neu-
rons expressing D2R mRNA by in situ hybridization with a riboprobe specific for D2R mRNA (blue) followed by 
immunohistochemistry with Cre specific antibody (brown). (d) Quantification of Cre positive neurons expressing D2R mRNA. 
Neurons expressing either Cre protein or D2R mRNA were also counted. Reported is the % of neurons per each group. The 
data are expressed as mean ± SEM. a-b-c are coronal sections; (a,b 400×; (b) 1000×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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formed with a probe for the Cre open reading frame. The
transgenic line was maintained by backcrossing to C57Bl/
6. To generate the respective mutant animals, the D1Cre
transgenic mice were first crossed to mice homozygous for
the respective loxP-modified allele. Offspring hemizygous
for the transgene and heterozygous for the loxP-modified
allele were in turn crossed to mice homozygous for the
loxP-modified allele to generate mutant animals with an
expected frequency of 25%. We did not observe cases of
germline recombination with this transgenic line.
Histology
Paraffin sections (7 μm) from mouse embryos at different
developmental stages and vibratome sections (50 μm)
prepared from brains of perfused mice (0.1 M phosphate-
buffered 4% paraformaldehyde) were used for immuno-
histochemical labeling. The following antibodies were
used: a rabbit polyclonal anti-Cre antibody (1:3,000,
[37]), a rabbit polyclonal anti-CREB antibody (1:3000), a
goat polyclonal anti-CaMKIV antibody (1:200, Santa
Cruz, cat. Sc-1546), a rabbit polyclonal GR antibody
(1:2000, Santa Cruz, cat. Sc-1004), a mouse monoclonal
anti class III beta-tubulin antibody (1:400, clone TujI,
Covance, cat. MMS-435P). Immunohistochemistry was
performed using the avidin-biotin system (Vectastain,
Vector Labs). Immunofluorescence was achieved using
Alexa488 coupled anti-rabbit antibody and an Alexa594-
coupled anti-mouse antibody (Molecular Probes) as sec-
ondary antibodies. Beta-galactosidase activity was
revealed by incubating embryos or vibratome sections at
37°C overnight in X-Gal staining solution (5 mM potas-
sium hexacyanoferrate (III), 5 mM potassium hexacyano-
ferrate (II), 2 mM MgCl2, 0.01% NP-40, 0.02% sodium
deoxycholate, 1 mg/ml X-gal, 20 mM Tris/HCl, pH7.5).
Non-radioactive in situ hybridization was performed on
vibratome sections (20 μm) prehybridized, after a step
with Proteinase K, at 70°C for 1 hour. Hybridization with
specific riboprobe occurs overnight at 70°C in the hybrid-
ization solution. After two washing steps the sections were
incubated with the anti-digoxygenin antibody (1:10000)
in 20% normal swine serum. The development of the
reaction was done with NBT/BCIP (Roche). After washing
in PBS and PBST, the sections were processed for immu-
nohistochemistry as described above.
Cell counting
To estimate the % of neurons expressing D2R and Cre,
cells positive for both signals were counted in nine nono-
verlapping microscopic field at 400× magnification. Neu-
rons expressing either Cre protein or D2R mRNA were
also counted. The data are expressed as mean ± SEM.
Retrograde tracing of striatonigral neurons
Mice were injected stereotaxically into the right and left
substantia nigra pars reticulata (AP = -3.28 mm, DV = -
4.15 mm, L = -1.3 mm and +1.3 mm) with 2 μl of a car-
boxylate-modified red latex FluoroSpheres solution
Pattern of recombination in adult Creb1D1Cre, CaMKIVD1Cre and GRD1Cre mice Figure 8
Pattern of recombination in adult Creb1D1Cre, CaMKIVD1Cre and GRD1Cre mice. Recombination is shown in striatum 
(a-f), hippocampus (g-l) and cortex (m-r). Recombination is followed by disappearance of CREB (a,b,g,h,m,n), CaMKIV 
(c,d,i,j,o,p) and GR proteins (e,f,k,l,q,r) in the respective mutants. All animals are homozygous for the respective loxP-modi-
fied allele in the case of Creb1loxP, CaMKIVloxP and GRloxP mice. Control animals are devoid of the D1Cre transgene while mutant 
animals carry the D1Cre trangene, as indicated. The hippocampus CA2 field is indicated by arrowheads. The cortical layers are 
indicated. Magnification: (a-f) 200×; (g-l) 50×; (m-r) 54×.BMC Neuroscience 2007, 8:4 http://www.biomedcentral.com/1471-2202/8/4
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(Molecular Probes, cat. L-2783,). Three days later, the ani-
mals were perfused through the ascending aorta with 0.1
M phosphate-buffered 4% paraformaldehyde and the
brains were removed to be postfixed for 4 hr at 4°C. Cre
immunofluorescence was performed on cryostat-cut free-
floating 30 μm-thick sections. Sections were examined on
a confocal microscope (MRC 1024, Bio-Rad Laboratories,
Hemel Hempstead, Hertfordshire, U.K.) fitted on an
inverted microscope (Axiovert 100, Zeiss, Oberkochen,
Germany).
List of abbreviations
YAC: yeast artificial chromosome; CREB: cAMP-respon-
sive element binding protein; CaMKIV: Ca2+/Calmodulin-
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D1R: dopamine D1 receptor; D2R: dopamine D2 receptor
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